This document appears to be page 41 of a confidential investment memorandum for 'New Leaf,' specifically regarding their third fund, NLV-III. It outlines the 'Medical Devices Investment Strategy,' emphasizing a shift toward later-stage opportunities due to regulatory headwinds in the U.S. and E.U. The document cites specific portfolio successes like Neuronetics, CardioKinetix, and the acquisition of Interlace Medical by Hologix to demonstrate the team's track record.
This document appears to be page 5 of a confidential investment memorandum for a fund named 'NLV-III' (likely New Leaf Ventures III). It outlines the investment thesis, citing a favorable regulatory environment due to increased FDA approvals and the FDASIA act of 2012, as well as favorable capital market dynamics caused by a contraction in venture capital fundraising which reduces competition for deals. The document bears a House Oversight Committee stamp, indicating it was part of a congressional investigation.
This document is an email chain from July 2009 between Jeffrey Epstein and Sultan Bin Sulayem. Bin Sulayem originally forwarded an article about global economic forecasts (IMF data), to which Epstein replied simply, 'mandelson is in london,' likely referring to British politician Peter Mandelson. The document bears a House Oversight Bates stamp.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity